Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide + bevacizumab in elderly patients with supratentorial glioblastoma and poor functional status
2009-014598-42Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and bevacizumab in glioblastoma (GBM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Overall survival. Started Jan 2010; status: active.
02
Drugs
temozolomidebevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-014598-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014598-42.